May 24, 2018
Novartis’s Zessly approved in Europe
Novartis’s Sandoz has secured European Commission’s approval for biosimilar Zessly, the company said Thursday.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
May 24, 2018
Real-world evidence shows weight loss in people receiving Saxenda
People treated with Saxenda for weight management lost an average of 8.1 kg after six months in a real-world clinical…
May 23, 2018
Lilly’s psoriasis treatment first FDA approved to include data in psoriasis involving the genital area
Eli Lilly said Tuesday that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz injection 80 mg/mL to…
May 22, 2018
Circassia Pharmaceuticals presents positive data from tested long-acting muscarinic antagonists
Circassia Pharmaceuticals showed positive clinical data from two studies of Tudorza and Duaklir, nearing the a deal with AstraZeneca in the United…
May 21, 2018
4D pharma to investigate MRx0518 in multiple cancer settings
The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared 4D pharma’s Clinical Trial Application for MRx0518, a live biotherapeutic…
May 21, 2018
AstraZeneca gets Lokelma approval
The US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults…
May 18, 2018
FDA approves Aimovig for migraine
The US Food and Drug Administration (FDA) has approved Novartis’s and Amgen’s Aimovig (erenumab) for the preventive treatment of migraine in…
May 16, 2018
Sanofi, Regeneron explore Dupixent’s role in targeting Type 2 inflammation as an underlying cause of atopic dermatitis
Sanofi’s pivotal Phase 3 test of Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents met its primary and key secondary…
May 16, 2018
Idorsia enrols first patient in study to test lucerastat as treatment for Fabry disease
Idorsia has enrolled the first patient in a Phase 3 registration study to investigate the effect of lucerastat, as an…
May 10, 2018
Lilly buys ARMO for $1.6 billion
Eli Lilly will buy ARMO BioSciences for $50 per share, or approximately $1.6 billion, the companies said Thursday.